MagicRNA Secures Nearly RMB 100 Million in Pre-A+ Financing to Advance In Vivo CAR-T Therapy HN2301

VCBeat has learned that Shenzhen Hongxin Biotechnology Co., Ltd. (“Hongxin Biotech,” MagicRNA) recently announced the completion of its Pre-A+ financing round, raising nearly RMB 100 million. This round was led byIDG CapitalLead Investor,GL VenturesandYuanBio Venture CapitalCo-investment, Existing ShareholdersHengye Sci-Tech InvestmentContinue to increase investment,Chenglin CapitalServed as the financial advisor for this round. The proceeds from this financing round will be used for the Investigational New Drug (IND) application and Investigator-Initiated Trial (IIT) clinical studies of the core product HN2301.

Hongxin Biologics, established in December 2021, is a research and development enterprise focused on nucleic acid drug delivery and innovative therapeutic mRNA drugs, dedicated to innovation and breakthroughs in nucleic acid drug delivery technologies. The company has developed a domestically leading library of ionizable amino lipids, with its core lipid (ILB3132) already commercialized.

To address the industry bottleneck of “extrahepatic and non-APC targeted delivery of mRNA,” Hongxin Bio successfully established its Engineered Cell-Targeted LNP (EnC-LNP) platform in 2023. Achieving international leadership in engineering and targeted delivery efficiency, the platform provides robust support for the precise delivery of nucleic acid therapeutics. The in vivo CAR-T pipeline developed based on the EnC-LNP platform completed dosing in the first patient with systemic lupus erythematosus (SLE) in the first quarter of 2025, marking the global first-in-human clinical trial for cell-targeted LNPs. Furthermore, this study achieved the first-ever in vivo CAR-T reprogramming and B-cell depletion in humans worldwide, demonstrating favorable safety profiles and preliminary clinical efficacy.

Pioneer in autoimmune CAR-T therapy and internationally renowned rheumatologist Professor Georg Schett officially joined the Advisory Board of Hongxin Biologics in May 2025, serving as Chief Medical Advisor. As a leading medical expert who pioneered the first global use of autologous CAR-T cell therapy for refractory autoimmune diseases and continues to drive clinical research and innovation in this field, Professor Schett will provide guidance on Hongxin Biologics’ clinical trials, R&D pipeline development, and FDA communications, thereby accelerating the clinical translation of its in vivo CAR-T therapies.

Dr. Cha Gaofeng, Founder of Hongxin Bio“We are deeply grateful for the investors’ recognition and support of Hongxin Bio. Founded in Shenzhen, Hongxin Bio has received strong backing from the Shenzhen Angel Fund of Funds and its subsidiary funds, including Zijingang Capital and YuanBio Venture Capital. This round of financing has further garnered recognition and support from numerous leading biopharmaceutical funds, signaling that Hongxin Bio has entered a new stage of development. The closing of the Pre-A+ round will accelerate the IND filing process for HN2301 and expedite clinical exploration of HN2301 in various autoimmune diseases where B-cell-mediated autoantibody production is the primary pathogenic mechanism, thereby further solidifying Hongxin Bio’s global leadership in in vivo CAR-T and engineered cell-targeted delivery technologies. We look forward to HN2301, this disruptive therapy, benefiting patients with autoimmune diseases as soon as possible.”

IDG Capitalstated: “Leveraging its forward-looking strategic layout, Hongxin Biology has achieved the number one global position in the in vivo CAR-T sector within just over three years of its establishment. We are optimistic about the potential of Hongxin Biology’s in vivo CAR-T pipeline to transform the treatment landscape for autoimmune diseases, and we believe that this investment will help the company further enhance its R&D capabilities and accelerate the clinical development of its core products.”

Ms. Ban Bo, Partner of YuanBio Venture Capital Shenzhen Angel Fund“Having followed Hongxin Biopharma for over two years, I have greatly admired Dr. Zha’s resilience in the face of adversity and his forward-looking strategic vision. Currently, Hongxin Biopharma’s HN2301 is at the forefront of global R&D progress. We are honored that YuanBio Venture Capital has participated in Hongxin Biopharma’s Pre-A+ financing round. We hope that our capital support will accelerate the subsequent development of the disruptive drug HN2301, thereby bringing clinical benefits to patients as soon as possible.”

IDG Capital has been rooted in China since 1993, conducting venture capital operations, and stands as one of the most active private equity fund managers in the Chinese market. With extensive investment experience and profound industry insights in consumer technology, healthcare, and consumer sectors, IDG Capital has invested in over 1,700 companies worldwide, achieving more than 600 exits through IPOs and mergers and acquisitions.

GL Ventures is one of the most active venture capital platforms in China, focusing on value discovery and value creation for innovative companies, with particular emphasis on key sectors such as new technologies, new energy, new materials, and new consumption. GL Ventures is committed to supporting the long-term development of early-stage innovative enterprises through systematic, in-depth value-creation services.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector. Headquartered in Suzhou BioBAY, it maintains a global reach. To date, YuanBio has invested in over 200 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 20 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging our professionalism, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.